Amgen

Profile narrative

Amgen is a biopharmaceutical company that discovers, develops, manufactures, and markets human therapeutics for a range of serious diseases. Its portfolio includes medicines used in oncology, cardiovascular health, inflammation, bone disease, nephrology, and neuroscience. The company works to translate scientific advances into treatments that address unmet medical needs for patients, healthcare providers, and health systems worldwide.

Amgen is headquartered in Thousand Oaks, California, and describes itself as a leading California-based biopharmaceutical enterprise. It maintains research and development centers, manufacturing facilities, and commercial operations in multiple regions across the globe. The organization’s products are distributed internationally, supporting patient care in numerous countries.

Amgen is recognized for its early contributions to recombinant DNA technology and the development of pioneering biologic medicines. It continues to invest heavily in its pipeline of investigational biologics and biosimilar candidates. As a publicly traded corporation listed on the NASDAQ under the ticker AMGN, Amgen operates as an independent entity without a parent company, overseen by a board of directors and executive management responsible for strategic direction, regulatory compliance, and oversight of its cybersecurity and risk management programs. In July 2026, the company disclosed a cybersecurity incident involving unauthorized access to third‑party cloud storage that resulted in the exfiltration of proprietary data and patient health information.

Incidents

1 incident linked to this organisation.